家兔动脉粥样硬化与血小板源内皮型氧化氮合酶表达的相关性

Objective To explore the correlation of atheroselerosis progression and the expression of platelet derived endothelial nitric oxide synthase (eNOS) in rabbits. Methods A total of 24 male New Zealand white rabbits were used in this study. Six of the animals were fed with normal food (control group). Eighteen rabbits were fed with cholesterol-rich food (1 g/d) for 12 weeks to establish the atherosclerosis model. Among 18 models, 6 rabbits were executed immediately and their aorta and platelet samples were collected for further analysis (model group), 6 rabbits were orally administered with pravastatin (10 rag/d) for additional 12 weeks (treated group), and the remaining 6 rabbits were left untreated until the end of the study (untreated group). The control, treated and untreated animals were then killed, and the aorta and platelet samples were collected for eNOS expression analysis (RT-PCR). Results The aorta samples in model and untreated group exhibited rough intima and a lot of longitudinal fatty streaks, which indicated that atherosclerosis models were established successfully. While in treated group, the degree of atherosclerosis was decreased. The average percent of thickness of fatty streaks or atheroselerotic plaques relative to the whole thickness of vessel walls was 0. 04±0. 02, 0. 82±0. 16, 0. 33±0. 18,0. 77±0. 14 in control, model, treated and untreated group, respectively. The thickness of fatty streaks or atherosclerotic plaques was significantly increased in the model and untreated groups and decreased in treated group compared with the control group (both P<0. 05). The expressions of platelet derived eNOS/mRNA were 1. 02± 0. 28, 0. 41± 0. 27, 1.00 ± 0. 77, 0. 40±0. 29 in control, model, treated and untreated group, respectively. The expression of eNOS/mRNA was markedly decreased in model group and untreated group compared with the control group, but was increased in treated group compared with untreated and model groups (F=3. 544, P = 0. 024). Conclusions There is a negative correlation between eNOS expression and atherosclerosis development, which suggests that the reversal effect of pravastatin on atheroselerosis progression and plaque formation may relate to the expression of platelet derived eNOS.     

家兔动脉粥样硬化与血小板源内皮型氧化氮合酶表达的相关性

Objective To explore the correlation of atheroselerosis progression and the expression of platelet derived endothelial nitric oxide synthase (eNOS) in rabbits. Methods A total of 24 male New Zealand white rabbits were used in this study. Six of the animals were fed with normal food (control group). Eighteen rabbits were fed with cholesterol-rich food (1 g/d) for 12 weeks to establish the atherosclerosis model. Among 18 models, 6 rabbits were executed immediately and their aorta and platelet samples were collected for further analysis (model group), 6 rabbits were orally administered with pravastatin (10 rag/d) for additional 12 weeks (treated group), and the remaining 6 rabbits were left untreated until the end of the study (untreated group). The control, treated and untreated animals were then killed, and the aorta and platelet samples were collected for eNOS expression analysis (RT-PCR). Results The aorta samples in model and untreated group exhibited rough intima and a lot of longitudinal fatty streaks, which indicated that atherosclerosis models were established successfully. While in treated group, the degree of atherosclerosis was decreased. The average percent of thickness of fatty streaks or atheroselerotic plaques relative to the whole thickness of vessel walls was 0. 04±0. 02, 0. 82±0. 16, 0. 33±0. 18,0. 77±0. 14 in control, model, treated and untreated group, respectively. The thickness of fatty streaks or atherosclerotic plaques was significantly increased in the model and untreated groups and decreased in treated group compared with the control group (both P<0. 05). The expressions of platelet derived eNOS/mRNA were 1. 02± 0. 28, 0. 41± 0. 27, 1.00 ± 0. 77, 0. 40±0. 29 in control, model, treated and untreated group, respectively. The expression of eNOS/mRNA was markedly decreased in model group and untreated group compared with the control group, but was increased in treated group compared with untreated and model groups (F=3. 544, P = 0. 024). Conclusions There is a negative correlation between eNOS expression and atherosclerosis development, which suggests that the reversal effect of pravastatin on atheroselerosis progression and plaque formation may relate to the expression of platelet derived eNOS.     

阵发性睡眠性血红蛋白尿患者外周血细胞CD47的表达

目的:通过研究阵发性睡眠性血红蛋白尿症(PNH)患者外周血细胞CD47的表达,探讨CD47在PNH发病机制中的作用。方法:选取PNH患者8例,正常对照组15例,以逆转录-聚合酶链反应异源双链分析银染法进行PIG-A基因检测,流式细胞术检测外周血细胞表面CD47、CD59的表达。结果:6例PNH患者PIG A基因第2外显子有碱基变异,其余2例未发现异常;PNH患者外周血红细胞、粒细胞CD47表达阳性率及平均荧光强度比正常对照组均减低(P<0．05)。结论:PNH患者外周血细胞表面CD47表达减少,CD47的表达与PNH发病机制可能有关。     

三七皂苷单体对高血压病人血小板功能的影响

目的:以硝苯地平及1{β[3-4-甲基苯丙氧基-甲氧苯]-1-H-盐酸咪唑}(SK&F96365)为对照,探讨三七皂苷单体人参皂苷-2A对血小板聚集功能的作用。方法:肘静脉采高血压病人血标本30份,正常人血标本30份,常规制备富含血小板血浆,分别用不同浓度的硝苯地平、SK&F96365、人参皂苷-2A孵育,以2μmol/L二磷腺苷为诱聚药,连续5次测定5分钟血小板的聚集率,以血小板最大聚集率(maximal platelet aggregation,PAGmax)为观察指标。结果:①高血压病人PAGmax为0.89±0.06,与正常人PAGmax0.68±0.07比较,差异有统计学意义(P<0.01);②两种浓度(10 μmol/L、20 μmol/L)的硝笨地平时正常人和高血压病人PAGmax均无影响;③4种浓度(2.5 μmol/L、5μmol/L、10μmol/L、20μmol/L)的SK&F96365对高血压病组的PAGmax均有抑制作用(均为P<0.05);④4种浓度(2.5μmol/L、5μmol/L、10μ,mol/L、20 μmol/L)的人参皂苷-2A对高血压病组的PAGmax均有抑制作用(均为P<0.05);3种浓度(5 μmol/L、10 μmol/L、20 μmol/L)的人参皂苷-2A对正常组的PAGmax均有抑制作用(均为P<0.05)。结论:高血压病人血小板聚集功能明显高于正常人,血小板呈高反应状态,是血栓形成的重要因素之一;硝苯地平不能抑制血小板聚集;SK&F96365能抑制血小板的聚集功能;人参皂     

血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂RGDS对血小板释放反应的影响

【目的】观察血小板膜糖蛋白Ⅱb/Ⅲa（GPⅡb/Ⅲa）拮抗剂——四肽Arg-Gly-Asp-Ser（RGDS）对血小板聚集和CD62p表达的作用,探讨RGDS对血小板聚集和释放反应的影响。【方法】检测二磷酸腺苷（ADP;终浓度5μmol/L,下同）诱导血小板聚集的最大聚集率（rPA,max）、静息血小板和ADP诱导的血小板CD62p表达,检测不同浓度RGDS对ADP诱导的rPA,max的抑制率和血小板CD62p表达的抑制率,进行回归分析。【结果】5种浓度（50、100、200、400、800μmol/L）的RGDS对rPA,max均有显著抑制作用。正常人静息血小板CD62p表达率为（3.5±0.6）%;ADP激动的血小板CD62p表达率为（65.6±13.8）%,两组比较有显著性差异（P〈0.01）;50、100μmol/L的RGDS对血小板CD62p表达无抑制作用;当RGDS浓度≥200μmol/L时（200、400、800μmol/L）,其可抑制血小板CD62p的表达;RGDS对rPA,max的抑制作用和其对血小板CD62p表达的抑制作用相关。【结论】RGDS浓度〈200μmol／L时，对ADP诱导的血小板释放反应无影响；RGDS浓度≥200μmol/L时，可抑制ADP诱导的血小板释放反应；与RGDS显著的抗聚集效应相比，其对血小板释放反应的影响比较小：RGDS抑制血小板释放反应的作用与其抗血小板聚集有关。     

血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂RGDS对血小板释放反应的影响

 【目的】观察血小板膜糖蛋白Ⅱb/Ⅲa（GPⅡb/Ⅲa）拮抗剂——四肽Arg-Gly-Asp-Ser（RGDS）对血小板聚集和CD62p表达的作用,探讨RGDS对血小板聚集和释放反应的影响。【方法】检测二磷酸腺苷（ADP;终浓度5μmol/L,下同）诱导血小板聚集的最大聚集率（rPA,max）、静息血小板和ADP诱导的血小板CD62p表达,检测不同浓度RGDS对ADP诱导的rPA,max的抑制率和血小板CD62p表达的抑制率,进行回归分析。【结果】5种浓度（50、100、200、400、800μmol/L）的RGDS对rPA,max均有显著抑制作用。正常人静息血小板CD62p表达率为（3.5±0.6）%;ADP激动的血小板CD62p表达率为（65.6±13.8）%,两组比较有显著性差异（P〈0.01）;50、100μmol/L的RGDS对血小板CD62p表达无抑制作用;当RGDS浓度≥200μmol/L时（200、400、800μmol/L）,其可抑制血小板CD62p的表达;RGDS对rPA,max的抑制作用和其对血小板CD62p表达的抑制作用相关。【结论】RGDS浓度〈200μmol／L时，对ADP诱导的血小板释放反应无影响；RGDS浓度≥200μmol/L时，可抑制ADP诱导的血小板释放反应；与RGDS显著的抗聚集效应相比，其对血小板释放反应的影响比较小：RGDS抑制血小板释放反应的作用与其抗血小板聚集有关。     

温抗体型自身免疫性溶血性贫血患者外周血细胞CD47的表达

[目的]探讨抗温体型自身免疫性溶血性贫血(AIHA)患者外周血细胞CD47的表达.[方法]应用流式细胞术检测15例AIHA外周血细胞CD47的表达,并与正常人及再生障碍性贫血(AA)患者进行比较.[结果]AIHA组、AA组及正常人外周血红细胞CD47表达阳性率分别为(90.37±5.36)%、(97.70±2.75)%、(97.02±5.62)%,平均荧光强度分别为25.47±11.87、37.80±16.47、35.21±10.81;AIHA组红细胞CD47的表达显著低于AA组及正常人(P均＜0.05);AIHA组、AA组及正常人外周血粒细胞CD47表达阳性率分别为(44.26±19.56)%、(52.33±14.74)%、(75.99±21.33)%,平均荧光强度分别为13.40±4.99、14.32±2.89、26.78±6.74;AIHA组、AA组粒细胞CD47的表达显著低于正常人(P＜0.05).[结论]AIHA患者外周血红细胞及粒细胞CD47表达缺失,AA患者粒细胞CD47表达缺失,红细胞CD47表达正常.     

二次异体造血干细胞移植成功治疗慢性髓系白血病1例

1病例报告 患者为男性,22岁,确诊慢性粒细胞性白血病慢性期(CML-CP)1年,Ph染色体100%阳性.供体为患者胞姐,HLA配型结果:血清学完全相合,基因分型(PCR-SSO)HLA-A位点亚型不合.于2003年7月9日入层流病房行异体造血干细胞移植术,第一次移植失败且自身造血未能恢复,而于9月2日(第一次移植后46 d)行第二次移植(同一供体),随访17个月,结果报告如下.     

充血性心力衰竭患者血清C反应蛋白水平与预后关系

目的 观察充血性心力衰竭(CHF)患者血清c反应蛋白(CRP)水平与预后关系.方法 选择342例CHF患者和126例健康者,应用酶联免疫法检测血清CRP水平.结果 CHF患者血清CRP为(8.66±4.38)mg/L,健康对照者为(1.12±0.87)mv:L(P<0.01).168例左室射血分数(LVEF)≤35%者,CRP水平为(11.92±4.55)mg/L,174例LVEF>35%者,CRP为(5/88±1.92)mg/L,LVEF值与CRP水平呈负相关(r=-0.502,P<0.01).心功能为Ⅰ、Ⅱ、Ⅲ、Ⅳ级者,其血清CRP分别为(3.92±0.79)mg/L、(5.03±1.55)me/L、(8.94±2.97)mg/L、(12.21±4.43)mg/L,随访6个月.其中血清CRP≥10 mg/L者病死率32.50%(26/83);5 mg/L≤CRP<10 mg/L者,病死率10.48%(11/109);CRP<5 mg/L者病死率2.76%(4/150).结论 CHF患者血清CRP水平升高程度与心力衰竭严重程度相平行,并预示患者预后不良.     

急性嗜酸粒细胞白血病1例报告

1 病例报告 患者,女,62岁.因头晕、头痛1个月,加重伴低热2日于2004-07-19入院.患者1个月前无明显诱因出现头晕、头痛、咽痛,无发热、耳鸣、呕吐及抽搐,在当地医院查血常规未见异常,经抗感染治疗(具体药物不详)后,头痛、咽痛消失,但头晕进行性加重,近两日出现低热.患者既往身体健康.